Shares of Bausch Health Companies Inc. (TSE:BHC - Get Free Report) rose 3% during mid-day trading on Thursday . The company traded as high as C$11.67 and last traded at C$11.61. Approximately 76,142 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 137,096 shares. The stock had previously closed at C$11.27.
Analyst Upgrades and Downgrades
Separately, Evercore ISI upgraded shares of Bausch Health Companies to a "hold" rating in a report on Tuesday, October 15th.
View Our Latest Analysis on BHC
Bausch Health Companies Trading Down 2.0 %
The company has a debt-to-equity ratio of 7,583.76, a quick ratio of 0.58 and a current ratio of 1.19. The stock has a market capitalization of C$4.18 billion, a P/E ratio of -6.50, a price-to-earnings-growth ratio of 0.21 and a beta of 0.77. The stock has a 50-day moving average price of C$11.63 and a two-hundred day moving average price of C$10.19.
Bausch Health Companies (TSE:BHC - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported C$1.53 earnings per share for the quarter, beating the consensus estimate of C$1.43 by C$0.10. The business had revenue of C$3.42 billion for the quarter, compared to analysts' expectations of C$3.36 billion. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 2,304.54%. On average, research analysts forecast that Bausch Health Companies Inc. will post 5.5472637 EPS for the current fiscal year.
Bausch Health Companies Company Profile
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
See Also
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
